MYC and cancer: Two factors can be selected for in rearrangement-driven cancers: oncogenic biochemical function in the case of a resulting fusion protein (Kadoch and Crabtree, 2013) and aberrant expression levels of a proto-oncogene (such as MYC or GFI1) via enhancer hijacking (Northcott et al., 2014).